Showing posts with label Cancer Market. Show all posts
Showing posts with label Cancer Market. Show all posts

ReportsandReports - The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities



In the current decade, oncology has been one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents (drug treatments developed to preferentially target those signaling pathways that are disregulated in tumors). Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.

In the current environment, the successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. In recent years, biotech companies have fuelled innovation in oncology more than ever before. Partnering with biotech companies is a key (but expensive) source of innovation for many pharma companies as approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.

At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, pricing risk remains the key investment concern in oncology. The key concern, however, is not price erosion driven by competitive forces, but price cuts imposed by payors irrespective of the fact that such unilateral price cuts by payors have never occurred in any of the major developed markets and would surely jeopardize the premise on which the entire biopharmaceutical industry has been built.

Key features of this report
  • Epidemiological analysis and forecast prevalence of the major cancer indications over the period 2008-14 including lung, breast, colorectal, ovarian cancer markets.
  • Forecasts and analysis of the major products in the cancer market over the period 2008-14 spread across the major indications and classes of treatments.
  • Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.
  • Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.
Scope of this report
  • Develop insight into patient potential with the report’s coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and 10 largest companies active in the cancer segment today
  • Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in cancer marketplace
  • Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players
  • Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities
Key Market Issues
  • FDA approves Cervarix for cervical cancer
    • In October 2009, FDA approved GSK’s Cervarix for the prevention of pre-cancerous lesions caused by human papillomavirus (HPV) type 16 & 18 in women aged 10-25 years. Cervarix’s inclusion in children’s vaccine program is a major step towards securing reimbursement. Cervarix, expected to launch by the end of 2009, faces direct competition from Merck’s Gardasil and will help to reduce the incidence of cervical cancer in future.
  • Merck’s Gardasil adds US indication of genital warts for boys and men
    • On 16th October 2009, Gardasil’s US label was extended to include its use in both men and boys aged 9-26 years of age. The pivotal trial results showed an efficacy of 90.4% while preventing external genital lesions of HPV types 6/11/16/18. In addition, Merck also planned to extend its vaccine patient assistance program providing free Gardasil to 19-26 year old uninsured males meeting eligibility criteria but unable to afford the vaccine.
Key findings from this report
  • In 2008, antineoplastic mAbs delivered huge sales of $13.6bn with a market share of 28.6% of total sales. The key antineoplastic mAbs which contributed to the higher market share of this class in 2008 were MabThera (11.0%), Avastin (10.3%), Herceptin (9.7%) and Erbitux (3.4%). Forecast sales of the total antineoplastics market are estimated at $65.2bn in 2014.
  • Roche is the global market leader in cancer, holding the highest market share of 29.2% ($14.0bn sales) in 2008 based on sales from (MabThera, Avastin, Herceptin, Tarceva and Xeloda). Roche’s strength in the cancer market has been bolstered by its acquisition of Genentech and purchase of majority stakes in Chugai, which has provided additional breadth to its portfolio.
  • Eli Lilly’s acquisition of ImClone will increase the former’s flow of high-quality, innovative new therapies. The transaction will immediately enable Eli Lilly to offer physicians and their patients a complementary portfolio of leading oncolytic agents and targeted therapies including Gemzar, Alimta and Erbitux.
Key questions answered
  • What will be the major growth indications in the cancer segment over the period 2008-14?
  • Which companies were the winners and losers in the cancer segment in 2008?
  • How have recent major launches from companies such as Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly performed?
  • Which companies will become the key players in the cancer segment over the period 2008-14?
  • Which products will be impacted by generic competitors over the period 2008-14?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , |

ReportsandReports - The Cancer Market Outlook to 2015: Competitive landscape, market size, pipeline analysis, and growth opportunities



Global cancer prevalence rates are on the rise owing to an aging population, changing lifestyle and increasing pollution. Prevalence data is significantly influenced by the increasing diagnosis and survival rates across the global market.

The global cancer market is becoming increasingly competitive, with two therapeutic classes namely antineoplastics and cytostatic hormonal treatments dominating this sector. Collectively, the top 10 products in the global cancer market accounted for majority of the revenue in 2009.

Oncology has become one of the major focus areas for pharmaceutical and biotechnology companies because of a high number of unmet needs for improved treatments in different types of cancer. In 2009, around 40,000 Phase I, II and III trials were listed on ClinicalTrials.gov, and approximately 40% of these were related to cancer.

Targeted therapies are revolutionizing the paradigm of cancer treatment and are likely to be used in most cancer patients in the next 10 years. Due to the high incidence and subsequent potential for market success, breast cancer and NSCLC continue to drive high levels of R&D (along with niche indications such as NHL, RCC, CML, and prostate cancer).

Another factor that plays a major role for the growth in the cancer therapy market is expansion of the target indications. Most of the blockbuster drugs were launched for a narrow indication, and were later approved for other indications. A classic example is imatinib, which was first approved by the FDA in 2001 for the treatment of CML and later was expanded to around nine different indications.

Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments. Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payors regarding the cost-effectiveness of cancer treatments has further intensified in the recent years.

Key Features of this report
  • Epidemiological analysis and forecast prevalence of the major cancer indications between 2009-15 including lung, breast, colorectal, and ovarian cancer markets.
  • Forecasts and analysis of the major products in the cancer market between 2009-15 spread across the major indications and classes of treatments.
  • Overview of key events in the global cancer market that have impacted treatment trends and sales potential across the major cancer indications.
  • Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.
  • Detailed analysis across major classes of cancer treatments including antineoplastics and cytotoxic hormone therapies.
  • Detailed analysis of the clinically differentiated products in the cancer pipeline by indication and sales forecast of key R&D pipeline products in the global cancer market.
Key Benefits of this report
  • Develop insight into patient potential with the report’s coverage of major indications in the cancer segment, the seven largest geographic pharmaceutical markets and the 10 largest companies active in the cancer segment today
  • Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive changes in the cancer marketplace
  • Gain up-to-date competitive intelligence across the cancer indications and understand the major issues affecting key pharmaceutical/biotech players
  • Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities
  • Compare the franchises of top pharmaceutical marketers across major indications, and understand how market share of leading companies will change over the next 6 years
  • Use head-to head comparisons of the leading cancer pipeline compounds to understand which companies will have a presence among key indications over the next 6 years
Key findings of this report

The global cancer market in 2009 was valued at around $50bn, an increase of nearly 6% over previous year sales, and is forecast to grow at a CAGR of more than 7% between 2009–15.

Antineoplastics formed the leading drug class for cancer treatment. While competition is strong within the antineoplastic market, four drugs dominated the global antineoplastics market – Roche’s Avastin (bevacizumab), MabThera (rituximab), and Herceptin (trastuzumab), and Novartis’s Glivec (imatinib).
Cytostatic hormone therapies formed the other major drug class in the global cancer market, which was led by cytostatic aromatase inhibitors, cytostatic gonad hormone analogs and cytostatic anti-androgens. Arimidex and Femara remained the leading drugs in cytostatic hormone therapy registering Y-o-Y growth of around 3% and 15% respectively in 2009.

In 2009, monoclonal antibodies (mAbs) accounted for the majority of sales, achieving almost 30% share among the top 10 brands in the global cancer market. This was largely driven by the commercial success of the mAb brands: MabThera, Avastin, and Herceptin.

Roche was the leading player in the cancer market in 2009, with its leading products Avastin, MabThera, Herceptin, Tarceva and Xeloda.

Although a large number of cancer vaccines are in development, Dendreon’s Provenge (sipuleucel-T) is the first therapeutic cancer vaccine which was approved in the US (April 2010) for the treatment of prostate cancer.

The top 10 true generic players in the cancer market represented 70% of the total generic market in 2009. Teva followed by Hospira remained the market leaders in the generic cancer market.

Key questions answered by this report
  • What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?
  • Who were the leading players in the cancer market in 2009?
  • Which products will be the future growth drivers for the cancer market?
  • Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009–15?
  • Which indications are forecast to have the highest levels of market potential over the period 2009–15?
  • What is the competitive landscape of key therapeutic areas?
  • Which companies are best positioned to succeed in the cancer market over the period 2009–15?
  • What are the significant market and pipeline developments that may shape corporate strategies for leading drug majors in this market?
  • How is the generic market performing?
  • How are the top 10 generic players positioned in the cancer market?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , |